These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25405143)

  • 1. Comparison of the efficacy of methotrexate and actinomycin D in the treatment of patients with stage I low risk gestational trophoblastic neoplasia (GTN).
    Shahbazian N; Razi T; Razi S; Yazdanpanah L
    Med J Islam Repub Iran; 2014; 28():78. PubMed ID: 25405143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia.
    Yarandi F; Eftekhar Z; Shojaei H; Kanani S; Sharifi A; Hanjani P
    Int J Gynaecol Obstet; 2008 Oct; 103(1):33-7. PubMed ID: 18632105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
    Lawrie TA; Alazzam M; Tidy J; Hancock BW; Osborne R
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD007102. PubMed ID: 27281496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.
    Uberti EM; Fajardo Mdo C; da Cunha AG; Frota SS; Braga A; Ayub AC
    Rev Bras Ginecol Obstet; 2015 Jun; 37(6):258-65. PubMed ID: 26200823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing biweekly single-dose actinomycin D with multiday methotrexate therapy for low-risk gestational trophoblastic neoplasia (FIGO Score 0-4): study protocol for a prospective, multicentre, randomized trial.
    Jiang F; Mao MY; Xiang Y; Lu X; Guan CL; Jiao LZ; Wan XR; Feng FZ; Ren T; Yang JJ; Zhao J
    BMC Cancer; 2023 Aug; 23(1):784. PubMed ID: 37612621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia.
    Hasanzadeh M; Tabari A; Homae F; Shakeri M; Bakhshandeh T; MadaniSani F
    J Cancer Res Ther; 2014; 10(3):646-50. PubMed ID: 25313754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial.
    Lertkhachonsuk AA; Israngura N; Wilailak S; Tangtrakul S
    Int J Gynecol Cancer; 2009 Jul; 19(5):985-8. PubMed ID: 19574798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
    Kang HL; Zhao Q; Yang SL; Duan W
    Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease.
    Lee YJ; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    J Gynecol Oncol; 2017 Mar; 28(2):e8. PubMed ID: 27819410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
    Miller CR; Chappell NP; Sledge C; Leath CA; Phippen NT; Havrilesky LJ; Barnett JC
    Gynecol Oncol; 2017 Jan; 144(1):125-129. PubMed ID: 27816248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of women diagnosed and treated for low-risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC).
    Verhoef L; Baartz D; Morrison S; Sanday K; Garrett AJ
    Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):458-463. PubMed ID: 28345753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.
    Cortés-Charry R; Hennah L; Froeling FEM; Short D; Aguiar X; Tin T; Harvey R; Unsworth N; Kaur B; Savage P; Sarwar N; Seckl MJ
    ESMO Open; 2021 Jun; 6(3):100110. PubMed ID: 33845362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate.
    Gilani MM; Fariba B; Behtash N; Ghaemmaghami F; Moosavi AS; Rezayof E
    J Cancer Res Ther; 2013; 9(1):38-43. PubMed ID: 23575072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.
    Lurain JR; Chapman-Davis E; Hoekstra AV; Schink JC
    J Reprod Med; 2012; 57(7-8):283-7. PubMed ID: 22838241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of MACT and 5Fu+ACT-D chemotherapy regimens in the treatment of low-risk gestational trophoblastic neoplasia.
    Wang Y; Miao JW; Wang T; Wang Y; Wu YM; Kong WM; Su L; Duan W
    J Chemother; 2016 Apr; 28(2):135-9. PubMed ID: 27105436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
    Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
    J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
    Chen YX; Shen YM; Qian JH; Xie X
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years.
    Fülöp V; Szigetvári I; Szepesi J; Végh G; Singh M; Berkowitz RS
    J Reprod Med; 2012; 57(7-8):310-8. PubMed ID: 22838247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia.
    Aminimoghaddam S; Nezhadisalami F; Anjidani S; Barzin Tond S
    Med J Islam Repub Iran; 2018; 32():36. PubMed ID: 30159287
    [No Abstract]   [Full Text] [Related]  

  • 20. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.
    Even C; Pautier P; Duvillard P; Floquet A; Kerbrat P; Troalen F; Rey A; Balleyguier C; Tazi Y; Leary A; Augereau P; Morice P; Droz JP; Fizazi K; Lhommé C
    Eur J Cancer; 2014 Aug; 50(12):2082-9. PubMed ID: 24910417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.